Rapid suppression of HIV-RNA is associated with improved control of immune activation in mozambican adults initiating antiretroviral therapy with low CD4 counts

AIDS Research and Human Retroviruses

Volumn 27, Issue 7, 2011, Pages 705-711

  Almeida, Jose M ^a   Letang, Emilio ^a,b   Nhampossa, Tacilta ^a,c   Ayala, Edgar ^b   David, Catarina ^a,c   Menendez, Clara ^a,b   Gascon, Joaquim ^b   Alonso, Pedro ^a,b   Naniche, Denise ^b  

^a Manhiça Health Research Center   (Mozambique)

^b UNIVERSITY OF BARCELONA   (Spain)

^c INSTITUTO NACIONAL DE SAÚDE   (Mozambique)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; COMBINATION CHEMOTHERAPY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALARIA; MALE; MOZAMBIQUE; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUBERCULOSIS; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MOZAMBIQUE; PROSPECTIVE STUDIES; RNA, VIRAL; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 79959815824     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2010.0200     Document Type: Article

References (39)

1. Demeter LM, Hughes MD, Coombs RW, et al.: Predictors of virologic and clinical outcomes in HIV-1-infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine. AIDS Clinical Trials Group Protocol 320. Ann Intern Med 2001;135:954-964. (Pubitemid 33131616)
2. Palella FJ, Jr, Delaney KM, Moorman AC, et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-860. (Pubitemid 28135961)
3. Gulick RM, Mellors JW, Havlir D, et al.: Treatment with in-dinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337:734-739. (Pubitemid 27417972)
4. Hammer SM, Squires KE, Hughes MD, et al.: A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997;337:725-733. (Pubitemid 27417971)
5. Montaner JS, Reiss P, Cooper D, et al.: A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: The INCAS Trial. Italy, The Netherlands, Canada and Australia Study. JAMA 1998;279:930-937. (Pubitemid 28136082)
6. Sterne JA, May M, Costagliola D, et al.: Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: A collaborative analysis of 18 HIV cohort studies. Lancet 2009;373:1352-1363.
7. World Health Organization: Scaling up antiretroviral therapy in resource-limited settings: treatment guidelines for a public health approach. World Health Organization, Geneva, 2005.
8. Stevens WS, Scott LE, and Crowe SM: Quantifying HIV for monitoring antiretroviral therapy in resource-poor settings. J Infect Dis 2010;201(Suppl 1):S16-26.
9. World Health Organization: WHO. Rapid advice: Anti-retroviral therapy for HIV infection in adults and adolescents, Geneva, 2009.
10. El-Sadr WM, Lundgren JD, Neaton JD, et al.: CD4\+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006;355:2283-2296. (Pubitemid 44837777)
11. Smit C, Geskus R, Walker S, et al.: Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion. AIDS 2006;20:741-749. (Pubitemid 43884302)
12. Bartlett JA and Shao JF: Successes, challenges, and limitations of current antiretroviral therapy in low-income and middle-income countries. Lancet Infect Dis 2009;9:637-649.
13. Munderi P: When to start antiretroviral therapy in adults in low-and middle-income countries: Science and practice. Curr Opin HIV AIDS 2010;5:6-11.
14. Wood E, Hogg RS, Harrigan PR, and Montaner JS: When to initiate antiretroviral therapy in HIV-1-infected adults: A review for clinicians and patients. Lancet Infect Dis 2005; 5:407-414. (Pubitemid 40840732)
15. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, and Markowitz M: Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373: 123-126.
16. Wei X, Ghosh SK, Taylor ME, et al.: Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995;373:117-122.
17. Perelson AS, Essunger P, Cao Y, et al.: Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 1997;387:188-191. (Pubitemid 27209434)
18. Metzner KJ, Allers K, Rauch P, and Harrer T: Rapid selection of drug-resistant HIV-1 during the first months of suppressive ART in treatment-naive patients. AIDS 2007; 21:703-711. (Pubitemid 46568627)
19. Townsend D, Troya J, Maida I, et al.: First HAART in HIV-infected patients with high viral load: Value of HIV RNA levels at 12 weeks to predict virologic outcome. J Int Assoc Physicians AIDS Care (Chic Ill) 2009;8:314-317.
20. Giorgi JV, Lyles RH, Matud JL, et al.: Predictive value of immunologic and virologic markers after long or short duration of HIV-1 infection. J Acquir Immune Defic Syndr 2002;29:346-355. (Pubitemid 34288887)
21. Hazenberg MD, Otto SA, van Benthem BH, et al.: Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS 2003;17:1881-1888. (Pubitemid 37070273)
22. Letang E, Almeida JM, Miro JM, et al.: Predictors of immune reconstitution inflammatory syndrome-associated with Ka-posi sarcoma in Mozambique: A prospective study. J Acquir Immune Defic Syndr 2010;53:589-597.
23. Nhacolo AQ, Nhalungo DA, Sacoor CN, Aponte JJ, Thompson R, and Alonso P: Levels and trends of demographic indices in southern rural Mozambique: Evidence from demographic surveillance in Manhica district. BMC Public Health 2006;6:291.
24. Manosuthi W, Sungkanuparph S, Tantanathip P, et al.: A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: The N2R Study. Clin Infect Dis 2009;48:1752-1759.
25. Manosuthi W, Sungkanuparph S, Thakkinstian A, et al.: Efavirenz levels and 24-week efficacy in HIV-infected patients with tuberculosis receiving highly active antiretroviral therapy and rifampicin. AIDS 2005;19:1481-1486. (Pubitemid 41400693)
26. Keiser P, Nassar N, White C, Koen G, and Moreno S: Comparison of nevirapine-and efavirenz-containing anti-retroviral regimens in antiretroviral-naive patients: A cohort study. HIV Clin Trials 2002;3:296-303. (Pubitemid 34830680)
27. Phillips AN, Ledergerber B, Horban A, et al.: Rate of viral rebound according to specific drugs in the regimen in 2120 patients with HIV suppression. AIDS 2004;18:1795-1804. (Pubitemid 39179631)
28. Ribaudo HJ, Kuritzkes DR, Lalama CM, et al.: Efavirenz-based regimens in treatment-naive patients with a range of pretreatment HIV-1 RNA levels and CD4 cell counts. J Infect Dis 2008;197:1006-1010. (Pubitemid 351590029)
29. Cozzi-Lepri A, Phillips AN, d'Arminio Monforte A, et al.: Virologic and immunologic response to regimens containing nevirapine or efavirenz in combination with 2 nucleoside analogues in the Italian Cohort Naive Antiretrovirals (I.Co.N.A.) study. J Infect Dis 2002;185:1062-1069. (Pubitemid 34297764)
30. van Leth F, Phanuphak P, Ruxrungtham K, et al.: Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: A randomised open-label trial, the 2NN Study. Lancet 2004;363:1253-1263. (Pubitemid 38496486)
31. Keiser O, Orrell C, Egger M, et al.: Public-health and individual approaches to antiretroviral therapy: Township South Africa and Switzerland compared. PLoS Med 2008;5:e148.
32. Matthews GV, Sabin CA, Mandalia S, et al.: Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: A cohort study. AIDS 2002;16:53-61. (Pubitemid 34062182)
33. Nachega JB, Hislop M, Dowdy DW, et al.: Efavirenz versus nevirapine-based initial treatment of HIV infection: Clinical and virological outcomes in Southern African adults. AIDS 2008;22:2117-2125.
34. Sodora DL and Silvestri G: Immune activation and AIDS pathogenesis. AIDS 2008;22:439-446. (Pubitemid 351317285)
35. Calmy A, Ford N, Hirschel B, et al.: HIV viral load monitoring in resource-limited regions: Optional or necessary? Clin Infect Dis 2007;44:128-134. (Pubitemid 44968997)
36. Lawn SD, Bekker LG, Calmy A, and Wood R: Monitoring of antiretroviral therapy in low-resource settings. Lancet 2008;372:287-288; author reply 289. (Pubitemid 352037426)
37. Mugyenyi P, Walker AS, Hakim J, et al.: Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): A randomised non-inferiority trial. Lancet 2010;375:123-131.
38. Mee P, Fielding KL, Charalambous S, Churchyard GJ, and Grant AD: Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa. AIDS 2008; 22:1971-1977.
39. Moore DM, Awor A, Downing R, et al.: CD4\+ T cell count monitoring does not accurately identify HIV-infected adults with virologic failure receiving antiretroviral therapy. J Ac-quir Immune Defic Syndr 2008;49:477-484.